LI KANG BIOMEDICAL Co. Ltd. Statistics
LI KANG BIOMEDICAL Co. Ltd. (6242) Stock Statistics & Valuation Metrics
Total Valuation
LI KANG BIOMEDICAL Co. Ltd. has a market cap or net worth of TWD 1.07B. The enterprise value is TWD 1.14B.
- Market Cap
- TWD 1.07B
- Enterprise Value
- TWD 1.14B
Share Statistics
LI KANG BIOMEDICAL Co. Ltd. has 31,806,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 31,806,500
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
LI KANG BIOMEDICAL Co. Ltd.’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 7.76%.
- Return on Equity (ROE)
- 0.10
- Return on Assets (ROA)
- 0.08
- Return on Invested Capital (ROIC)
- 7.76%
- Return on Capital Employed (ROCE)
- 0.11
- Revenue Per Employee
- 4.53M
- Profits Per Employee
- 644.80K
- Employee Count
- 130
- Asset Turnover
- 0.54
- Inventory Turnover
- 4.17
Valuation Ratios
The current PE Ratio of LI KANG BIOMEDICAL Co. Ltd. is 13.90. LI KANG BIOMEDICAL Co. Ltd.’s PEG ratio is -1.29.
- PE Ratio
- 13.90
- PS Ratio
- 1.86
- PB Ratio
- 1.26
- Price to FCF
- -6.21
- Price to Operating Cash Flow
- 12.93
- PEG Ratio
- -1.29
Income Statement
In the last 12 months, LI KANG BIOMEDICAL Co. Ltd. had revenue of 589.21M and earned 83.82M in profits. Earnings per share was 2.64.
- Revenue
- 589.21M
- Gross Profit
- 398.25M
- Operating Income
- 98.28M
- Pretax Income
- 104.05M
- Net Income
- 83.82M
- EBITDA
- 113.22M
- Earnings Per Share (EPS)
- 2.64
Cash Flow
In the last 12 months, operating cash flow was 82.06M and capital expenditures -253.74M, giving a free cash flow of -171.68M billion.
- Operating Cash Flow
- 82.06M
- Free Cash Flow
- -171.68M
- Free Cash Flow per Share
- -5.42
Dividends & Yields
LI KANG BIOMEDICAL Co. Ltd. pays an annual dividend of ―, resulting in a dividend yield of 5.97%
- Dividend Per Share
- ―
- Dividend Yield
- 5.97%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -16.11%
- Earnings Yield
- 7.20%
Stock Price Statistics
- Beta
- 0.25
- 52-Week Price Change
- -14.65%
- 50-Day Moving Average
- 33.74
- 200-Day Moving Average
- 35.25
- Relative Strength Index (RSI)
- 12.75
- Average Volume (3m)
- 5,291
Important Dates
LI KANG BIOMEDICAL Co. Ltd. upcoming earnings date is Mar 05, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 11, 2026
- Next Earnings Date
- Mar 05, 2027
- Ex-Dividend Date
- ―
Financial Position
LI KANG BIOMEDICAL Co. Ltd. as a current ratio of 1.50, with Debt / Equity ratio of 17.03%
- Current Ratio
- 1.50
- Quick Ratio
- 1.23
- Debt to Market Cap
- 0.08
- Net Debt to EBITDA
- 0.93
- Interest Coverage Ratio
- 264.20
Taxes
In the past 12 months, LI KANG BIOMEDICAL Co. Ltd. has paid 20.23M in taxes.
- Income Tax
- 20.23M
- Effective Tax Rate
- 0.19
Enterprise Valuation
LI KANG BIOMEDICAL Co. Ltd. EV to EBITDA ratio is 12.61, with an EV/FCF ratio of -6.79.
- EV to Sales
- 2.03
- EV to EBITDA
- 12.61
- EV to Free Cash Flow
- -6.79
- EV to Operating Cash Flow
- 14.21
Balance Sheet
LI KANG BIOMEDICAL Co. Ltd. has TWD 178.22M in cash and marketable securities with TWD 160.52M in debt, giving a net cash position of TWD 17.70M billion.
- Cash & Marketable Securities
- TWD 178.22M
- Total Debt
- TWD 160.52M
- Net Cash
- TWD 17.70M
- Net Cash Per Share
- TWD 0.56
- Tangible Book Value Per Share
- TWD 26.59
Margins
Gross margin is 67.22%, with operating margin of 15.21%, and net profit margin of 13.32%.
- Gross Margin
- 67.22%
- Operating Margin
- 15.21%
- Pretax Margin
- 16.32%
- Net Profit Margin
- 13.32%
- EBITDA Margin
- 16.12%
- EBIT Margin
- 14.88%
Analyst Forecast
The average price target for LI KANG BIOMEDICAL Co. Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -0.93%
- EPS Growth Forecast
- -10.65%
